Will 2.5mg of Mounjaro do anything — and what should you expect?

The myth: 2.5mg is so low it's basically a placebo

This is the most common concern our prescribers hear. People start their first pen, feel broadly normal, step on the scales after a fortnight, and wonder whether anything is happening at all. The short answer is: yes, something is happening, just not the thing most people are watching for.

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1, which together slow gastric emptying, damp down appetite signals and influence how the body processes blood sugar. At 2.5mg those effects are present but deliberately mild. Eli Lilly designed this starting point specifically to reduce the nausea, vomiting and diarrhoea that can occur when the full pharmacological effect hits an unprepared gut. The NHS patient information for tirzepatide confirms that 2.5mg is a starting dose for tolerability, not the level at which treatment is expected to work at full effect.

Think of it as the first week of a new exercise programme: your cardiovascular system is adapting even if you can't yet see a difference in the mirror. If you're weighing up whether 2.5mg of Mounjaro will work for your situation, it helps to understand that the absence of dramatic early weight loss is not a sign the medicine is failing you. It is the system working exactly as intended. If you want a broader picture of how the medicine fits together, the Mounjaro overview covers the full mechanism and licensed indications.

What people do (and don't) notice at 2.5mg

Responses at the starter dose vary considerably. A meaningful number of people report noticeably reduced appetite within the first week, smaller portions feeling satisfying, or simply thinking about food less. Others notice mild nausea after the injection, particularly in the first day or two. Both of these are the medicine doing something; neither guarantees a particular weight outcome.

What most people do not notice at 2.5mg is a rapid change on the scales. In the large-scale SURMOUNT-1 trial, the headline weight-loss figures of around 20–21% at the 15mg dose were achieved over 72 weeks, not four. The early weeks at lower doses are part of that trajectory, not separate from it. Published trial data, reviewed in NICE's appraisal of tirzepatide (TA1026), support the phased titration approach precisely because most of the weight-loss effect accumulates as the dose climbs.

One quick habit worth building: note how full you feel after a regular meal on day three or four of your first pen, then compare it to how you felt before you started. That subtle shift in satiety is often the earliest measurable sign that tirzepatide is active in your system. Our guide to the Mounjaro 2.5mg pen covers what to expect from that first injection, including how to use it and what a normal early response looks like.

Side effects at 2.5mg, when they occur, are usually mild. The most common are gastrointestinal, loose stools, nausea, a feeling of fullness that lingers a little longer than normal. For most people these settle within a few days. If you're curious whether what you're experiencing is typical, our FAQs address the most common early questions.

When do the therapeutic effects actually begin?

From 5mg onwards, most people start to see more noticeable appetite suppression and (given the lifestyle changes that should accompany treatment) early weight movement. This is not a hard rule; some people feel a meaningful effect at 2.5mg and some need to reach higher doses before much shifts. A prescriber's job is to track that individual response and guide the pace of titration accordingly.

The licensed titration schedule moves upward in roughly four-week steps, with doses of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg available in the UK. Your prescriber decides when to increase based on how well you tolerated the previous dose, not on a rigid calendar. If you're wondering what typically changes between the first and second pen, the page on Mounjaro 5mg goes into that transition in detail. The question of whether you'll lose weight specifically at 2.5mg is addressed more directly on the will I lose weight on 2.5mg Mounjaro page.

It's also worth knowing that if 2.5mg feels manageable, that is genuinely useful clinical information. A smooth first month means your prescriber has good grounds to move you to 5mg with confidence. Struggling with tolerability at the starter dose, by contrast, is a signal to stay there a little longer, and that is fine too. There is no failure attached to the pace.

Eligibility, oversight, and what comes next

Mounjaro is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability, a prescriber weighs the full clinical picture.

Because this is a prescription-only medicine, every dose increase is a clinical decision, not an automatic step. At nume, a GPhC-registered Independent Prescriber reviews your case personally before each supply, no algorithm, no rubber-stamping. Information about what that review involves and who conducts it is on our about page. If cost is a factor in your thinking, the Mounjaro cost page sets out what private treatment typically involves and what a transparent price should include. And if you'd like to understand your wider treatment options before committing to anything, the weight-loss treatment overview is a good place to start.

The NHS patient information page for tirzepatide, available on NHS.uk, also explains the dosing schedule and what to expect, written in plain English for patients. Reading it alongside your Patient Information Leaflet is worth doing before your first pen.

If you think Mounjaro could be right for you, the next step is a clinical assessment. Check your eligibility with our prescribers, the consultation is free, and there's no obligation.